TheEdgeResearch
Home / Stocks / TRRI

Alzex Neuropharma Inc. (TRRI)

OTC Basic Materials Other Precious Metals
$0.00 ▲ +0.00%
Market Cap
$1,054
Sector
Basic Materials
Industry
Other Precious Metals
Beta
-4.12
52-Wk Range
0.000099999997-0.0012
CEO
Robert W. Rosner
Country
US
Currency
USD

Alzex Neuropharma Inc. operates in the Other Precious Metals industry of the Basic Materials sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1,054. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of -4.12 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.01
Price / Sales
0.00
Price / Book
-0.00
EV / EBITDA
-0.56
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.42
Current ratio
0.08
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
11
IPO date
2009-10-23
Headquarters
Las Vegas, NV, US
About Alzex Neuropharma Inc.

Alzex Neuropharma Inc. is a development-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and other neurological disorders, based on assets and intellectual property acquired from Alzex Biomedical Group Inc. in 2022. Formerly known as Trinity Resources Inc., a mineral exploration company, it adopted its current name in December 2022. The company is based in Henderson, Nevada.

Comparable companies

Alzex Neuropharma Inc. is most often compared with the following Basic Materials names:

ASKEBKSLFCMIMCNTOGPLDFGRENQGRSFRKTEURPLFZNXT
More research on TRRI
TRRI technical analysis TRRI TheEdge Score Compare against peers
Open full interactive analysis & DCF →